Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liverdisease (NAFLD), now sometimes called metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when excess fat is stored in the liver in the absence of heavy alcohol usage. It is the most prevalent chronic liver disease in Western countries, affecting roughly 24% of U.S. adults and approximately 1 billion individuals worldwide.

NAFLD has two types: simple fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), where fat promotes inflammation and liver damage. NASH occurs in about 25-30% of NAFLD patients and may progress to cirrhosis, liver failure, or malignancy.

Obesity and Insulin resistance Type 2 diabetes High triglycerides Abnormal cholesterol Metabolic syndrome High blood pressure Poor diet Lack of exercise Rapid weight loss Risk factors: NAFLD is usually a quiet condition and may not cause any symptoms; however, some people may feel tired or have discomfort in the upper right part of the abdomen.

NAFLD raises the risk of diabetes, cardiovascular disease, and kidney damage. There are no FDA authorised drugs at this time; however, the main treatment is weight loss. Losing 3–5% of body weight reduces liver fat while decreasing weight by 7–10% reduces inflammation and fibrosis. Regular exercise, proper food, and steady weight decrease lead to better outcomes. Managing underlying conditions, such as diabetes, is important for keeping your liver healthy in the long term.